Floatz logo

Nivolumab

Myelodysplastic Syndrome/Acute Myeloid Leukemia

National Cancer Institute (NCI)monoclonal_antibodyPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Myelodysplastic Syndrome/Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Azacitidine
City of Hope Medical Center
Phase 2/3BB
Decitabine
National Cancer Institute (NCI)
Phase 2/3B
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2/3B
Midostaurin
National Cancer Institute (NCI)
Phase 2/3B
Irinotecan
National Cancer Institute (NCI)
Phase 2CCC

View all 21 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →